Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exact Sciences Cor
(NQ:
EXAS
)
65.54
-1.85 (-2.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Exact Sciences Cor
< Previous
1
2
Next >
Exact Sciences to Participate in September Investor Conferences
August 28, 2024
From
Exact Sciences Corp.
Via
Business Wire
Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG)
August 23, 2024
Via
AB Newswire
Exposures
COVID-19
Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study
August 20, 2024
From
Exact Sciences Corp.
Via
Business Wire
New Modeling Data Show the Cologuard® Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion
August 15, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences Announces Second-Quarter 2024 Results
July 31, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences schedules second quarter 2024 earnings call
July 08, 2024
From
Exact Sciences Corp.
Via
Business Wire
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
June 18, 2024
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including
Via
MarketBeat
Exact Sciences to Participate in June Investor Conferences
May 28, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®
May 24, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences Earns 2024 Great Place To Work® Certification™
May 22, 2024
From
Exact Sciences Corp.
Via
Business Wire
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
May 21, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences Announces First-Quarter 2024 Results
May 08, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024
May 07, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences to Participate in May Investor Conference
May 01, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
April 15, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
April 11, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
April 08, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences Schedules First Quarter 2024 Earnings Call
April 08, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
April 04, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
March 28, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
March 27, 2024
From
Exact Sciences Corp.
Via
Business Wire
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
March 13, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer
March 07, 2024
From
Exact Sciences Corp.
Via
Business Wire
3 Hot Stocks Bought by Members of Congress: Follow the Money
March 01, 2024
Palo Alto Networks, Simon Property Group and JPMorgan Chase are the top three stocks bought by Members of Congress in February;
Via
MarketBeat
Exact Sciences to Participate in March Investor Conference
February 26, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences Announces Fourth Quarter 2023 Results
February 21, 2024
From
Exact Sciences Corp.
Via
Business Wire
Exact Sciences Schedules Fourth Quarter 2023 Earnings Call
February 01, 2024
From
Exact Sciences Corp.
Via
Business Wire
Time to buy these 3 healthcare companies that raised revenue guidance?
January 16, 2024
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance.
Via
MarketBeat
Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience
September 12, 2023
From
Agilent Technologies Inc.
Via
Business Wire
ARKK: The Pros and Cons Of Buying Into Cathie's Best-Known ETF
July 13, 2023
If you're a believer in the progress of science and technology and feel strongly that our best days are still ahead, then a slice of ARKK could be tempting.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.